Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 4Lymphoma, Non-Hodgkin 4Cytokine Release Syndrome 4Prostatic Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Renal Cell 2Thrombocytosis 1Thrombocytopenia 1Smoldering Multiple Myeloma 1Schwannomatosis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pain 1Ovarian Neoplasms 1Neurilemmoma 1Neoplasms by Histologic Type 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × siltuximab × Clear all
NCT01024036 2018-03-21

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Janssen Research & Development, LLC

Phase 2 Completed
79 enrolled 20 charts

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Neoplasms

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Centocor, Inc.

Phase 2 Terminated
106 enrolled 13 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡